Polymorphisms inXRCC1,XRCC3, andCCND1and Survival After Treatment for Metastatic Breast Cancer
- 20 December 2006
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (36) , 5645-5651
Abstract
Purpose: Single nucleotide polymorphisms (SNPs) in DNA repair and cell cycle control genes may alter protein function and therefore the efficacy of DNA damaging chemotherapy. We retrospectively evaluated the association of SNPs in DNA repair genes, XRCC1-01 (Arg399Gln) and XRCC3-01 (Thr241Met), and a cell cycle control gene, CCND1-02 (A870G), with progression-free survival (PFS) and breast cancer specific survival (BCSS) in patients with metastatic breast cancer (MBC).Patients and Methods: SNPs in 95 patients with MBC enrolled onto one of five prospective clinical trials of high-dose chemotherapy and autologous stem-cell transplantation were evaluated using genotyping assays.Results: For XRCC1-01, the hazard ratio (HR) for BCSS was 2.8 (95% CI, 1.60 to 5.00) and the HR for PFS was 2.0 (95%CI, 1.12 to 3.43). For XRCC3-01, the HR for BCSS was 2.0 (95%CI, 1.12 to 3.70) and the HR for PFS was 2.0 (95%CI, 1.09 to 3.59). For CCND1-02, the HR for BCSS was 1.8 (95%CI, 1.12 to 2.78) and the HR for PFS was 1.8 (95%CI, 1.15 to 2.85). Patients carrying one variant genotype (HR, 1.7; 95%CI, 1.07 to 2.82) or combinations of any two variant genotypes (HR, 4.7; 95% CI, 2.41 to 8.94) had significantly poorer BCSS compared with patients carrying zero variants. In multivariable analysis, XRCC1-01, presence of liver metastases, and bone metastases independently predicted BCSS. Combinations of any two variant genotypes were stronger independent predictors of BCSS and PFS than the presence of liver or bone metastases.Conclusion: XRCC1-01, XRCC3-01, and CCND1-01 may be predictive of survival outcome in patients with MBC treated with DNA damaging chemotherapy.Keywords
This publication has 61 references indexed in Scilit:
- Cyclin D1: polymorphism, aberrant splicing and cancer riskOncogene, 2006
- Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinomaCancer, 2005
- New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapyAnnals of Oncology, 2005
- GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in SingaporeEuropean Journal of Cancer, 2005
- Nucleotide-excision repair and prostate cancer riskCancer Letters, 2005
- Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancerBreast Cancer Research and Treatment, 2005
- Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian CancerClinical Cancer Research, 2004
- DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tractInternational Journal of Cancer, 2004
- DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer riskCancer Detection Prevention, 2004
- Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposureCancer Detection Prevention, 2004